Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer (original) (raw)
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
Brooke Mccollum
Neoplasia, 2020
View PDFchevron_right
Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Rene Houtman
Clinical Cancer Research
View PDFchevron_right
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
Hisham Mohammed
Cancers, 2021
View PDFchevron_right
960 ASC-J9® Suppresses Castration-Resistant Prostate Cancer Growth via Degradation of Full-Length and Splice Variant Androgen Receptors
Tatsuo Tochigi
The Journal of Urology, 2012
View PDFchevron_right
A New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
Iain McEwan
Journal of Medicinal Chemistry
View PDFchevron_right
A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
Jonathan Melamed
Cancer Research, 2009
View PDFchevron_right
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
Maria Mudryj
Biomedicines
View PDFchevron_right
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
Yingming Li
2013
View PDFchevron_right
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Charles Sawyers
Proceedings of the National Academy of Sciences, 2010
View PDFchevron_right
Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Akira Yokomizo
Current Cancer Drug Targets, 2011
View PDFchevron_right
A new compound targets the AF-1 of androgen receptor and decreases its activity and protein levels in prostate cancer cells
CHIN-HEE Song
2020
View PDFchevron_right
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Peter Rix, Anna Aparicio, Jeffrey Hager, Beatrice Darimont
Cancer Research, 2012
View PDFchevron_right
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Simon Haile, Iain McEwan
Cancer Cell, 2010
View PDFchevron_right
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami
Communications biology, 2018
View PDFchevron_right
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer
Inna Shyshynova
Cell Cycle, 2009
View PDFchevron_right
Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
Kenneth Pienta
Cancer Research, 2009
View PDFchevron_right
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Asish Pati
Frontiers in Oncology, 2020
View PDFchevron_right
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
Sarah Loddick
Bioorganic & Medicinal Chemistry Letters, 2013
View PDFchevron_right
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
scott lawrence
Nature Chemical Biology, 2016
View PDFchevron_right
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Ilsa Coleman
Journal of Clinical Investigation, 2010
View PDFchevron_right
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
Dong-Jin Hwang
International Journal of Molecular Sciences
View PDFchevron_right
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan Rice
Frontiers in Oncology
View PDFchevron_right
Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells
Sunita Shinde
Assay and drug development technologies, 2016
View PDFchevron_right
Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal
Yingming Li
Journal of Biological Chemistry, 2012
View PDFchevron_right
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-maarit Moilanen, Olli Törmäkangas
Scientific Reports, 2015
View PDFchevron_right
Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation
Vincent Njar
Cancers
View PDFchevron_right
Overview on the complexity of androgen receptor-targeted therapy for prostate cancer
Ammad Farooqi
Cancer Cell International, 2015
View PDFchevron_right
Splicing variants of androgen receptor in prostate cancer
Yanfeng Qi
American journal of clinical and experimental urology, 2013
View PDFchevron_right
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
Rupert Fray
Frontiers in Endocrinology
View PDFchevron_right
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Daniel Nava Rodrigues
Clinical Cancer Research, 2020
View PDFchevron_right
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
Yanfeng Qi
Oncotarget, 2014
View PDFchevron_right
Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models
Vincent Njar
Cells
View PDFchevron_right
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
Josef Fox
Journal of Clinical Oncology, 2013
View PDFchevron_right